Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftriaxone Prophylaxis for TACE in Hepatocellular Carcinoma
NCT05654896Phase 3Unknown
- Start
- Nov 2022
- Primary completion
- Nov 2023
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of ceftriaxone in liver abscess. Status: unknown.
02
Drugs
ceftriaxone
03
Conditions
liver abscess
Beyond the preview
Go deeper on NCT05654896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05654896.